A multicenter retrospective study showed that aspirin use was independently related to an increased objective response rate among 1012 cancer patients (52.2% NSCLC, 26% melanoma, 18.3% renal cell carcinoma and 3.6% others) treated with PD-1/PD-L1 inhibitors (Cortellini et al., 2020), and a meta-analysis reported that concurrent use of low-dose aspirin was associated with better progression-free survival in cancer patients receiving immune checkpoint inhibitors, including NSCLC (Zhang et al., 2021). This evidence concerns the gene CD274 and non-small cell lung carcinoma.